lisocabtagene maraleucel


( Last Updated : July 9, 2021)
Generic Name:
lisocabtagene maraleucel
Project Status:
Pending
Therapeutic Area:
Relapsed or refractory large B-cell lymphoma
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
PG0258-000
Call for patient/clinician input closed:

Details


Manufacturer Requested Reimbursement Criteria1:
​For the treatment of adult patients with relapsed or refractory (R/R) large B-cell lymphoma including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma (PMBCL), and follicular lymphoma grade 3B (FL3B) after at least 2 prior therapies.
Submission Type:
Initial
Fee Schedule:
Pending
Tumour Type:
Lymphoma
Indications:
​Lisocabtagene maraleucel is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory (R/R) large B-cell lymphoma including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma (PMBCL), and follicular lymphoma grade 3B (FL3B) after at least 2 prior therapies.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.